Imaging Core

成像核心

• 批准号: 8764764
• 负责人: Henry Charles Manning
• 金额: $ 12.12万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-09-01 至 2018-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8764764
• 关键词: Address; Animals; Apoptosis; Basic Science; Biological Assay; Biological Markers; Biological Process; Biology; Breast; Breast Cancer Treatment; Cancer Center; Chemistry; Clinical; Clinical Drug Development; Clinical Sciences; Clinical Trials; Collaborations; Data; Development; Diagnosis; Drug Targeting; Engineering; Equipment; Faculty; Fluorescence; Fostering; Funding; Goals; Grant; Histology; Housing; Human Resources; Image; Image Analysis; Imaging Techniques; In Situ; Inflammation; Institutes; Instruction; Laboratories; Magnetic Resonance; Magnetic Resonance Imaging; Mammary Neoplasms; Medicine; Metabolism; Methods; Metric; Mission; Molecular; Monitor; Patient Care; Philosophy; Physics; Pilot Projects; Play; Positron-Emission Tomography; Preparation; Protocols documentation; Research; Research Personnel; Research Support; Resource Development; Resources; Roentgen Rays; Role; Science; Services; Techniques; Tissues; Translational Research; Translations; Ultrasonography; Universities; X-Ray Computed Tomography; angiogenesis; anticancer research; assay development; base; bioimaging; cancer initiation; cancer therapy; cost effective; drug distribution; forging; imaging modality; in vivo; innovation; instrument; malignant breast neoplasm; molecular imaging; molecular/cellular imaging; non-invasive imaging; novel; pre-clinical; receptor expression; response; single photon emission computed tomography; tool; treatment response; tumor initiation

The overall goal of the Imaging Core is to develop, optimize, implement, and validate quantitative, surrogate predictive biomarkers of: 1) drug target engagement, 2) the type of antitumor effect induced by a particular treatment, and 3) the response of breast cancer to treatment. The Imaging Core will offer a full range of small animal functional, anatomical, and molecular imaging techniques, including magnetic resonance, computed tomography, ultrasound, fluorescence, single photon emission computed tomography (SPECT) and positron emission tomography (PET) imaging. Breast SPORE investigators will also have access to novel probe development resources, including high-throughput, diversity-oriented synthesis capabilities suitable for identifying novel imaging compounds, as well as the resources of the state-of-the-art Vanderbilt University Research Radiochemlstry Core. Novel and established molecular imaging techniques will be offered which are specifically tailored for assessing quantitative metrics of cellular metabolism and proliferation, apoptosis, angiogenesis, receptor expression and inflammation. As in the previous funding cycle, the Imaging Core will continue to partner with other Cores in the SPORE and forge new connections with the VUIIS such that services are highly cost-effective. To provide this support to the projects, the Imaging Core has identified the following three specific alms: 1. Foster collaborations between experts in advanced, quantitative non-invasive imaging and breast cancer research. In particular, the Core will support experts in all major imaging modalities, with particular emphasis on positron emission tomography (PET) and magnetic resonance imaging (MRI). 2. Develop, validate, and provide non-invasive imaging metrics of drug distribution, drug target engagement, tumor initiation, progression and treatment response for Breast SPORE investigators. 3. Provide support for analysis of quantitative imaging data, development of customized imaging protocols, including the co-registration and integration of multiple imaging modalities, histology and other in situ assays, and the development of novel imaging biomarkers.

成像核心的总体目标是开发、优化、实施和验证定量、替代 预测性生物标志物：1）药物靶点接合，2）由特定靶点诱导的抗肿瘤作用的类型， 治疗，和3）乳腺癌对治疗的反应。成像核心将提供全方位的小型 动物功能、解剖和分子成像技术，包括磁共振、计算机 断层扫描、超声、荧光、单光子发射计算机断层扫描（SPECT）和正电子 发射断层扫描（PET）成像。Breast SPORE研究人员还将获得新型探头 开发资源，包括高通量、面向多样性的合成能力，适用于 鉴定新的成像化合物，以及最先进的范德比尔特大学的资源 放射化学研究中心。将提供新的和建立的分子成像技术， 专门定制用于评估细胞代谢和增殖，凋亡， 血管生成、受体表达和炎症。与上一个融资周期一样，成像核心将 继续与SPORE中的其他核心合作，并与VUIIS建立新的联系， 服务具有很高的成本效益。为了向项目提供这种支持，成像核心已经确定了 以下三个具体的施舍： 1.促进先进的定量非侵入性成像和乳腺癌专家之间的合作 癌症研究。特别是，核心将支持所有主要成像模式的专家， 特别强调正电子发射断层扫描（PET）和磁共振成像（MRI）。 2.开发、验证和提供药物分布、药物靶点的非侵入性成像指标 乳腺孢子研究者的参与、肿瘤发生、进展和治疗反应。 3.为定量成像数据分析、定制成像开发提供支持 协议，包括多种成像模式、组织学和 其他原位测定和新的成像生物标志物的开发。